WAYNE, PA — Teleflex Incorporated (NYSE: TFX) said it remains focused on completing previously announced asset sales and pursuing its strategic plan after responding to claims made by Irenic Capital Management.
Teleflex said its board and management met with Irenic on March 19, 2026, after the investor requested discussions and urged the company to initiate a public strategic alternatives process.
The company said Irenic mischaracterized the discussions and denied claims that its board instructed advisors to reject acquisition interest.
Teleflex said it has not received proposals to acquire its remaining business but would evaluate any credible offer in the context of long-term value.
The company said previously announced divestitures of its Acute Care, Interventional Urology and OEM businesses remain on track to close in the second half of 2026.
Teleflex expects the transactions to generate approximately $1.8 billion in net proceeds after tax, which it plans to use for a $1.0 billion share repurchase and $800 million in debt reduction.
The company said it is also advancing a multi-year restructuring plan expected to deliver about $50 million in annual pre-tax cost savings by mid-2028, with some savings beginning in 2026.
Teleflex completed the acquisition of BIOTRONIK’s vascular intervention business in July 2025 and said the move expanded its presence in coronary and peripheral intervention markets.
The company said it continues to search for a permanent chief executive officer, with interim CEO Stu Randle overseeing current operations and strategic initiatives.
Teleflex said its board is focused on completing divestitures, improving financial performance and executing its long-term strategy to enhance shareholder value.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.